Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71018 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Nathaniel J Macatangay und 2 weiteren Autor:innen. Beteiligte Einrichtung: Children's Hospital, University of Missouri Health Care, Columbia, Missouri, USA. Hauptthemen laut MEDLINE: Tobramycin, Anti-Bacterial Agents, Ciliary Motility Disorders, Cystic Fibrosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
Patients with primary ciliary dyskinesia (PCD) are commonly treated for pulmonary exacerbations with intravenous tobramycin, but data on tobramycin pharmacokinetics in PCD is lacking. The objective of this study was to compare tobramycin pharmacokinetics in pediatric patients with PCD to those with cystic fibrosis (CF).
Methods
This retrospective study included pediatric patients hospitalized for a pulmonary exacerbation between January 2018 and June 2023. Included patients were treated with systemic tobramycin and had two concentrations usable to calculate patient‐specific pharmacokinetics. Each patient with PCD was matched 1:2 to patients with CF based on age. The primary outcome was tobramycin elimination rate constant.
Results
Seven patients with PCD were matched to 14 patients with CF. Baseline characteristics were similar between groups. The final tobramycin dose was not significantly different between groups (9.3 vs. 11.8 mg/kg, p = 0.192). All doses were infused over 30 min every 24 h. Tobramycin elimination rate constant (0.510 vs. 0.493 h −1 , p = 0.433) and volume of distribution (0.31 vs. 0.23 L/kg, p = 0.640) were not different between groups. No patient experienced acute kidney injury. Additionally, both groups experienced similar duration of tobramycin therapy (12.3 vs. 9.6 days, p = 0.184) and length of stay (12.0 vs. 12.6 days, p = 0.801).
Conclusions
No difference in tobramycin elimination rate constant was found between patients with PCD and those with CF. Clinical outcomes were not significantly different between groups. Although not statistically significant, a lower tobramycin dose was observed in patients with PCD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's Hospital, University of Missouri Health Care, Columbia, Missouri, USA.
- Riley Hospital for Children, Indiana University Health, Indianapolis, Indiana, USA.
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Macatangay, N. J., Engdahl, S., & Pettit, R. S. (2025). Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71018
Vancouver
Macatangay NJ, Engdahl S, Pettit RS. Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71018
BibTeX
@article{Macatangay2025,
author = {Macatangay, Nathaniel J and Engdahl, Samantha and Pettit, Rebecca S},
title = {Tobramycin Pharmacokinetics in Pediatric Patients With Primary Ciliary Dyskinesia},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71018}
}
EUVIMED